News
This saves patients hours annually, time they can spend with family, at work, or relaxing, while also offering major ...
England's National Health Service will soon offer nivolumab as a quick injection for cancer patients. This new method cuts ...
Participants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...
The complete remission of a testicular cancer patient receiving Mink Therapeutics Inc.’s allogeneic, off-the-shelf invariant natural killer T-cell therapy Agent-797 with nivolumab drove the company’s ...
Most patients with advanced melanoma treated with pre-surgical immunotherapy remained alive and free of disease four years post-treatment.
Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...
Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...
Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have demonstrated that the NeoVax personalised cancer ...
Modified Herpes Virus as a Weapon Against Skin Cancer? A new study suggests it might work—even for metastases deep within the ...
Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...
Results of a Dana-Farber Cancer Institute-initiated phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine called ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results